Miles Fisher (editor) - Diabetes Drug Notes

Edited by

MILES FISHER, GERARD A. MCKAY, AND ANDREA LLANO

Glasgow Royal Infirmary, Glasgow, UK

This edition first published 2022

2022 John Wiley & Sons Ltd

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.

The right of Miles Fisher, Gerard A. McKay, and Andrea Llano to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

Registered Offices

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office

9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data
Names: Fisher, Miles, editor. | McKay, Gerard A., editor. | Llano, Andrea, editor.
Title: Diabetes drug notes / edited by Miles Fisher, Gerard A. McKay, Andrea Llano.
Description: Hoboken, NJ : Wiley-Blackwell, 2022. | Includes bibliographical references and index. | Contents: Clinical pharmacology of antidiabetic drugs / Andrea Llano, Gerry McKay, and Ken Paterson -- Metformin / Joseph Timmons and James Boyle -- Sulfonylureas and meglitinides -- Joseph Timmons and James Boyle -- DPP-4 inhibitors / Sharon Mackin and Gemma Currie -- SGLT2 inhibitors / Miles Fisher, Andrea Llano, and Gerry McKay -- GLP-1 receptor agonists / Catherine Russell and John Petrie -- Animal and human insulin / Ken Paterson -- Short-acting insulin analogues / Kate Hughes and Gerry McKay -- Long-acting Insulin Analogues / Robert Lindsay -- Devices / David Carty -- Acarbose and alpha glucosidase inhibitors / Miles Fisher -- Glitazones and glitazars / Miles Fisher -- Other antidiabetic drugs / Maroria Oroko, Andrea Llano, and Miles Fisher -- Future antidiabetic drugs / Emma Johns and Miles Fisher -- Guidelines / Miles Fisher and Russell Drummond -- Prescribing antidiabetic drugs / Andrea Llano, Gerry McKay, Frances McManus, Catriona McClements, Joyce McKenzie, and Deborah Morrison.
Identifiers: LCCN 2022020904 (print) | LCCN 2022020905 (ebook) | ISBN 9781119785002 (paperback) | ISBN 9781119785019 (pdf) | ISBN 9781119785026 (epub) | ISBN 9781119785033 (ebook)
Subjects: MESH: Hypoglycemic Agents--pharmacology | Glycoside Hydrolase Inhibitors--pharmacology | Insulins-- pharmacology | Diabetes Mellitus--drug therapy
Classification: LCC RC661.I6 (print) | LCC RC661.I6 (ebook) | NLM WK 825 | DDC 616.4/62061--dc23/ eng/20220608
LC record available at https://lccn.loc.gov/2022020904
LC ebook record available at https://lccn.loc.gov/2022020905

Cover image: Milos Dimic/Getty Images, Jose Luis Pelaez/Getty Images, MirageC/Getty Images

Cover design by Wiley

Set in 10/12pt STIXTwoText by Integra Software Services Pvt. Ltd, Pondicherry, India

1. Chapter 1
2. Chapter 2
3. Chapter 3
4. Chapter 4
5. Chapter 5
6. Chapter 6
7. Chapter 7
8. Chapter 8
9. Chapter 9
10. Chapter 10
11. Chapter 11
12. Chapter 12
13. Chapter 13
14. Chapter 14

1. Chapter 1
2. Chapter 5
3. Chapter 6
4. Chapter 7
5. Chapter 10
6. Chapter 14
7. Chapter 15
8. Chapter 16

1. Chapter 1
2. Chapter 2
3. Chapter 3
4. Chapter 4
5. Chapter 5
6. Chapter 6
7. Chapter 7
8. Chapter 8
9. Chapter 9
10. Chapter 10
11. Chapter 11
12. Chapter 12
13. Chapter 13
14. Chapter 14
15. Chapter 15
16. Chapter 16

As the prevalence of diabetes continues to escalate, the delivery of individualised, effective, and well-tolerated treatment has become ever more prescient. Achieving adequate glycaemic control is a fundamental therapeutic objective across the spectrum of diabetes presentations in order to defer and address complications and co-morbidities. Type 2 diabetes accounts for the majority of people with diabetes, and the management of this disease is made particularly difficult by its heterogeneity and variable natural history. Type 1 diabetes requires the fine-tuning of insulin replacement to maintain quality and quantity of life. Recent years have seen the availability of an increasing range of therapies that target different aspects of the pathophysiology, but how can these drugs be used to best effect?

This book explains the rationale that underpins the selection of antidiabetic drugs and offers clear practical know-how advice to guide healthcare professionals through the pharmacotherapy of diabetes. Each class of antidiabetic drug receives comprehensive coverage, supported by evidence from key clinical trials and real-world usage. The text is conveniently structured for a duality of purpose, such that it successfully provides detailed pharmacology for the specialist while also offering straightforward clinical pointers for the non-specialist.